Kanghua Biological: The conversion of construction projects to fixed assets will be strictly executed in accordance with relevant regulations

Kanghua Biological stated on the 15th while answering investor questions on the interactive platform that the company's construction projects are converted to fixed assets in strict accordance with corporate accounting standards and relevant regulations, and the conversion is processed in a timely manner based on the specific construction progress of the project and the conditions for reaching the predetermined usable state. The vaccine production expansion project of Kanghua Biological is currently in the review stage of the supplementary application for drug production license, and the project will enhance the production capacity of the company's core product, lyophilized human rabies vaccine, after it is put into production